Haemonetics Earnings Reports

Haemonetics reported a 3.7% increase in revenue compared to the third quarter of fiscal 2024, with a notable 23.9% growth in the Hospital business unit. The company's adjusted earnings per diluted share increased by 14.4% to $1.19, and cash on hand increased by $142.0 million since the end of fiscal 2024.

Haemonetics Corporation reported an 8.6% increase in revenue for the second quarter of fiscal 2025, with significant growth in the Hospital business unit. The company's adjusted earnings per diluted share increased by 13.1% to $1.12. Haemonetics updated its fiscal 2025 revenue guidance and reaffirmed its adjusted operating margin, adjusted earnings per diluted share, and free cash flow guidance.

Haemonetics reported an 8% increase in revenue to $336 million for the first quarter of fiscal year 2025. The company reaffirmed its fiscal year 2025 guidance for revenue, adjusted operating margin, adjusted earnings per diluted share, and free cash flow.

Haemonetics reported strong fourth quarter and fiscal year 2024 results, with revenue increasing by 13% to $343 million. The company advanced its market leadership through strategic investments and acquisitions, contributing to revenue growth and margin expansion.

Haemonetics Corporation reported a 10.1% increase in revenue for the third quarter of fiscal 2024, reaching $336.3 million. The company's adjusted earnings per diluted share increased by 22.4% to $1.04. They updated their fiscal 2024 guidance for total revenue growth to 10-12% and adjusted earnings per diluted share to $3.90 - $4.00.

Haemonetics reported a 7% increase in revenue for the second quarter of fiscal year 2024, reaching $318 million. The company's adjusted earnings per diluted share increased by 19.3% to $0.99. They have also updated their fiscal 2024 guidance with increased expectations for revenue, adjusted operating margin, adjusted EPS, and free cash flow.

Haemonetics Corporation reported a strong first quarter in fiscal year 2024, with a 19% increase in revenue to $311 million and adjusted earnings per diluted share of $1.05. The company's performance was driven by market-leading results across all business segments and advancements in innovation and commercial pipelines.

Haemonetics Corporation reported a 14.9% increase in revenue for the fourth quarter of fiscal year 2023, reaching $304.4 million. Earnings per diluted share were $0.57, and adjusted earnings per diluted share were $0.77. The company provided fiscal year 2024 revenue and earnings guidance.

Haemonetics Corporation reported a 17.5% increase in revenue for the third quarter of fiscal 2023, reaching $305.3 million. Earnings per diluted share increased to $0.64, and adjusted earnings per diluted share rose to $0.85. The company updated its fiscal 2023 revenue and earnings guidance, reflecting confidence in its performance.

Haemonetics reported a strong second quarter in fiscal year 2023, with revenue increasing by 24% to $297.5 million. The company's plasma and hospital business units showed significant growth, and Haemonetics updated its fiscal year 2023 guidance, projecting higher revenue and earnings per share.

Haemonetics reported a strong fourth quarter, with revenue up 17.8% to $265 million. The company saw growth across its business units, particularly in Hospital, and managed to mitigate inflationary pressures through its Operational Excellence Program. Adjusted earnings per diluted share increased by 41.3% to $0.65.

Haemonetics reported an 8.1% increase in revenue to $259.8 million for the third quarter of fiscal year 2022. Earnings per diluted share were $0.45, and adjusted earnings per diluted share reached $0.84. The company updated its fiscal 2022 revenue growth guidance to 12-14% and organic revenue growth to 5-7%.

Haemonetics Corporation reported a 14.5% increase in revenue compared to the second quarter of fiscal 2021. The company's Plasma and Hospital businesses are expected to continue growth in the second half of fiscal 22.

Haemonetics' first quarter fiscal 2022 performance showed a positive start to the year, driven by recovery across all businesses, especially Hospital, and initial Plasma Persona® rollouts. The company remains confident in strong end-market demand and anticipates full recovery from the pandemic by the end of the fiscal year. The revised Operational Excellence Program aims to enhance quality, service, and productivity, offsetting impacts from customer loss, the pandemic, and inflationary pressures.

Haemonetics reported a decrease in Q4 revenue by 5.6% to $225 million, primarily driven by the continued impact of COVID-19. The company experienced an operating loss of $21.2 million, and a net loss of $11.0 million, or $0.22 per share. Adjusted earnings per diluted share were $0.46. The company issued its FY2022 revenue growth guidance of 13–18%.

Haemonetics reported a 7.2% decrease in revenue to $240.4 million for Q3 2021, impacted by COVID-19. However, profitability improved due to the Operational Excellence Program and cost management. The company is progressing with NexSys® and TEG® adoption and investing in innovation.

Haemonetics reported a decrease in revenue for the second quarter of fiscal year 2021 due to the impact of COVID-19, but operating income increased due to gains on divestitures. The company is focused on completing its turnaround, delivering operational excellence, and advancing its innovation agenda.

Haemonetics reported a decrease in revenue for Q4 2020, with a 4.3% drop to $238.5 million. However, the company saw improvements in gross margin, which rose by 300 basis points to 47.6%, and operating income, which increased by 9.0% to $26.0 million. Net income decreased by 15.4% to $17.6 million, with earnings per diluted share down 15.0% to $0.34.

Haemonetics reported a 4.7% increase in revenue compared to the third quarter of fiscal year 2019. The company's value drivers are powering revenue and earnings growth, and they are transforming their product portfolio, reducing complexity, and advancing operational excellence.